Immunotherapy in Urothelial Bladder Cancer: Current Treatments and Emerging Research

In this CME-certified program, experts discuss emerging data on immunotherapy treatment for urothelial bladder cancer. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium for expert guidance on how to use immunotherapy treatment in your care of patients with bladder cancer.
Matthew Galsky, MD
Elizabeth R. Plimack, MD, MS

Downloadable Slideset

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, explores the current clinical data on the use of immune checkpoint inhibitor-based therapy for patients with metastatic urothelial carcinoma.

Elizabeth R. Plimack, MD, MS Released: November 7, 2019

In this downloadable slideset, Matthew Galsky, MD, reviews the most recent data and ongoing clinical trials assessing the efficacy of immune checkpoint inhibitor-based therapy for patients with muscle-invasive bladder cancer.

Matthew Galsky, MD Released: November 7, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?